Lupus vasculitis

Last updated
Lupus vasculitis
Cutaneous small-vessel vasculitis.jpg
Cutaneous small-vessel vasculitis. Bilateral palpable purpura and necrotic lesions
Specialty Rheumatology

Lupus vasculitis is one of the secondary vasculitides that occurs in approximately 50% of patients with systemic lupus erythematosus (SLE). [1]

Contents

Large vessel involvement is extremely uncommon; medium-sized vessels can also be impacted, but small vessels are the most frequently linked to it. Lupus vasculitis can affect multiple organ systems and show up as a wide range of clinical manifestations depending on the location and size of the affected vessels. [2]

Lupus vasculitis typically indicates a dismal prognosis, so early diagnosis is essential to a successful outcome. [2] The disease can affect small vessels or a single organ, and it can range in severity from a relatively mild condition to a multiorgan system disease with potentially fatal symptoms, like mesenteric vasculitis, [3] pulmonary hemorrhage, [4] or mononeuritis multiplex. [5]

The organs affected and the severity of the vasculitis process determine the course of treatment. [6]

Signs and symptoms

Cutaneous vasculitis is the most common type of vasulitis amongst those with systemic lupus erythematosus. [7] The clinical presentation is variable and can include superficial ulcerations, splinter hemorrhages, panniculitis, macules, erythema with necrosis or erythematous plaques, cutaneous infarction, livedo reticularis, bullous lesions of the extremities or urticaria lesions, papulonodular lesions, petechiae, and palpable purpura. [8] The majority of skin lesions are composed of nodular lesions, erythema of the hand dorsum, and discoid erythematosus lesions, which are typically found on the fingertips. [9] Most of the time, small vessels—primarily post-capillary venules—are involved. Less commonly, medium-vessel vasculitis manifests as ischemic ulcers or subcutaneous nodules. [2]

Patients with SLE may experience peripheral and central nervous system vasculitis. The most prevalent clinical manifestation at the peripheral level is mononeuritis multiplex. Rather than affecting many nerves diffusely, it affects a single nerve focally or multifocally. Clinical manifestations consist of peripheral neuropathy affecting at least two distinct nerve areas that is asymmetrical, progressive, and asynchronous, as well as weakness, pain, and sensory loss. [5] Contiguous nerves are affected as the disease progresses, resulting in a syndrome that resembles a generalized polyneuropathy. [10] Patients with SLE may also develop a mild-to-moderately-severe peripheral symmetric sensory polyneuropathy. [11] At the central level, the most commonly reported clinical features that may manifest concurrently or independently during the course of the disease are seizure disorders, cerebrovascular disease, demyelinating syndrome, and cognitive dysfunction. [12]

Lupus enteritis, or SLE-related vasculitis of the gastrointestinal tract, is a rare condition; the estimated prevalence of SLE patients is 9.7%. [13] Lupus mesenteric vasculitis is a common manifestation of gastrointestinal vasculitis in SLE. [14] One of the most deadly consequences of SLE is lupus mesenteric vasculitis, which has a 50% death rate when severe, occlusive damage leads to bowel ischemia and possible small- or large-bowel necrosis, which can then develop into perforation and bleeding. [3] The main symptoms are bloating, diarrhea, vomiting, nausea, hematemesis, melena, and acute abdominal pain. [15] Urinary symptoms such as dysuria and lupus cystitis may be associated with lupus mesenteric vasculitis in about 22.7% of cases. [16]

The least common renal vascular injury associated with lupus nephritis is true renal vasculitis, which has not been widely documented in the literature. It was discovered after the fact in renal biopsies in 2.8%, [17] 2.4%, [18] and 0.6% of cases. [19] Although the clinical manifestations of various vascular lesions differ, SLE patients with renal vasculitis typically exhibit anemia, glomerular lesions, hematuria, hypertension that often worsens the vascular changes, high SLEDAI scores, and severe renal insufficiently with rapid progression to renal failure. [20]

Rarely is retinal vasculitis reported as a complication in case reports. [21] Usually, involvement occurs in the precapillary superficial arterial vasculature. [22] Retinal vasculitis may manifest as asymptomatic or with decreased vision, painless blurred vision or permanent vision loss. [23]

Few case reports of coronary vasculitis have been documented in the literature, making it an uncommon illness. [24] It frequently shows up in the absence of laboratory evidence of active SLE and clinical SLE flare. [25] There have also been isolated reports of myocardial dysfunction brought on by small vessel vasculitis and cardiac valve malfunction. [26]

Diffuse alveolar hemorrhage, which results from red blood cells entering the alveolar spaces as a result of extensive pulmonary vessel damage and disruption of the alveolar-capillary basement membrane, is the most frequent clinical manifestation of lupus pulmonary vasculitis. [27] In more than 60% of cases, symptoms can include fever, chest pain, hemoptysis, coughing, and progressive and severe dyspnea. It's possible for some patients to have no symptoms. [4]

Causes

Lupus vasculitis is a secondary vasculitis that may manifest in the form of acute or subacute lupus symptoms as a result of an inflammatory process caused by immune complex deposition within blood vessel walls. [28] On the other hand, it might manifest as comorbidity linked to steroids (steroid-related atherosclerosis) or as the combined pathogenetic effect of heightened atherosclerosis in a proinflammatory milieu. [29]

Mechanism

The development of lupus vasculitis is not fully understood. It involves complex interactions between an aggressive immune response against the body's own cells, inflammatory changes, and blood vessels. Immune complexes (made up of antibodies that mistakenly attack self-proteins) get deposited in blood vessel walls, which triggers an inflammatory response that damages these blood vessels over time. [30] Injury to blood vessels can cause the vessel wall to thicken which prevents adequate blood flow to organs, or to weaken which leads to bleeding into the surrounding tissues.

Various autoantibodies have been identified in the development of lupus vasculitis including anti-endothelial cell antibodies (AECA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-phospholipid antibody (aPL), and anti-double stranded DNA (anti-dsDNA). [30] Other processes that may contribute to the progression of vasculitis include changes in cell death signaling and impaired clearance of dying cells.

Other forms of vasculitis in SLE patients can be caused by drugs or infections. In drug-induced lupus vasculitis, the drug molecule forms a hapten that triggers an intense immune response within the vasculature. Some of these drugs include penicillin, thiazides, monoclonal antibodies, and carbamazepine. [31] [30] Infection-induced lupus vasculitis involves the direct attack of pathogens on vessel walls with subsequent immune complex deposition, inflammation, and injury to blood vessels. [30] [32]

Diagnosis

Skin biopsies from individuals who had lupus cutaneous vasculitis showed secondary changes to the overlying epidermis and sweat glands, variable fibrinoid necrosis of the vessel walls, and fragmented neutrophilic nuclei (a leukocytoclastic variant). [30]

Nervous system vasculitis affecting the peripheral nervous system is histologically characterized by chronic axonal degeneration, necrotizing, or occlusive vasculitis of the vasa nervorum, and demyelination. [33] For clinicians, diagnosing central nervous vasculitis can be difficult. The gold standard for the diagnosis is a brain biopsy, but because the vascular lesions are segmental in nature, this is a highly invasive procedure with limited sensitivity. Without a brain biopsy, an early diagnosis can frequently be made using a combination of neuroimaging, clinical features, and relevant diagnostic investigations. [12]

Computed tomography (CT), which visualizes the abdominal vasculature as well as the colon wall, is the gold standard for diagnosing gastrointestinal vasculitis. Bowel wall edema, target signs, intestinal segment dilatation, increased attenuation of mesenteric fat,  prominent mesenteric vessels, and ascites are typical tomographic findings. [34]

Fluorescein angiography and optical coherence tomography are two types of retinal imaging that can be useful in diagnosing and characterizing retinal vasculitis. [21]

Serial coronary angiographic studies that reveal arterial aneurysms, tapered stenoses, and/or rapidly forming arterial occlusions are typically used to diagnose coronary vasculitis. [26]

Treatment

The European League Against Rheumatism's (EULAR) updated recommendations for SLE serve as a clinical benchmark, but the course of treatment for lupus vasculitis should be determined by the severity of the condition and its accompanying symptoms. [6] Typically, oral corticosteroids and immunosuppressants like mycophenolate mofetil, azathioprine, and methotrexate are used to treat mild-to-moderate symptoms. For the severe and potentially fatal forms, a more aggressive course of treatment including intravenous high-dose corticosteroids, rituximab, cyclophosphamide,  intravenous immunoglobulin, and/or plasmapheresis is taken into consideration. [26]

Several serious complications of lupus vasculitis that require immediate and aggressive treatment include the GI tract (mesenteric vasculitis with bowel ischemia), nervous system (seizures, transverse myelitis, multiple mononeuropathy), or lungs (diffuse alveolar hemorrhage). [30] Currently, there lacks clinical trials specific for the treatment of lupus vasculitis. Due to this limitation, therapy recommendations are often made based on treatment for other autoimmune disease or vasculitis syndromes. [31] [30]

Milder symptoms are commonly treated with oral corticosteroids and immunosuppressants such as methotrexate or azathioprine. Severe cases require more aggressive therapy with high-dose intravenous corticosteroids, monoclonal antibodies, cyclophosphamide, intravenous immunoglobulin (IVIG), or plasmapheresis. [31] [30] For skin involvement, some reported therapies include hydroxychloroquine, colchicine, mycophenolate mofetil, or rituximab. [31] [30]

See also

Related Research Articles

<span class="mw-page-title-main">Polyarteritis nodosa</span> Medical condition

Polyarteritis nodosa (PAN) is a systemic necrotizing inflammation of blood vessels (vasculitis) affecting medium-sized muscular arteries, typically involving the arteries of the kidneys and other internal organs but generally sparing the lungs' circulation. Small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an important diagnostic feature of the vasculitis. PAN is sometimes associated with infection by the hepatitis B or hepatitis C virus. The condition may be present in infants.

Mixed connective tissue disease, commonly abbreviated as MCTD, is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP), together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

<span class="mw-page-title-main">Discoid lupus erythematosus</span> Autoimmune skin condition

Discoid lupus erythematosus is the most common type of chronic cutaneous lupus (CCLE), an autoimmune skin condition on the lupus erythematosus spectrum of illnesses. It presents with red, painful, inflamed and coin-shaped patches of skin with a scaly and crusty appearance, most often on the scalp, cheeks, and ears. Hair loss may occur if the lesions are on the scalp. The lesions can then develop severe scarring, and the centre areas may appear lighter in color with a rim darker than the normal skin. These lesions can last for years without treatment.

<span class="mw-page-title-main">Lupus erythematosus</span> Collection of human autoimmune diseases

Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.

Cerebral vasculitis is vasculitis involving the brain and occasionally the spinal cord. It affects all of the vessels: very small blood vessels (capillaries), medium-size blood vessels, or large blood vessels. If blood flow in a vessel with vasculitis is reduced or stopped, the parts of the body that receive blood from that vessel begins to die. It may produce a wide range of neurological symptoms, such as headache, skin rashes, feeling very tired, joint pains, difficulty moving or coordinating part of the body, changes in sensation, and alterations in perception, thought or behavior, as well as the phenomena of a mass lesion in the brain leading to coma and herniation. Some of its signs and symptoms may resemble multiple sclerosis. 10% have associated bleeding in the brain.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaques, usually on the trunk.

Lupus erythematosus panniculitis presents with subcutaneous nodules that are commonly firm, sharply defined and nontender.

Rheumatoid vasculitis is skin condition that is a typical feature of rheumatoid arthritis, presenting as peripheral vascular lesions that are localized purpura, cutaneous ulceration, and gangrene of the distal parts of the extremities.

<span class="mw-page-title-main">Systemic vasculitis</span> Medical condition

Necrotizing vasculitis, also called systemic necrotizing vasculitis, is a general term for the inflammation of veins and arteries that develops into necrosis and narrows the vessels.

<span class="mw-page-title-main">Lupus</span> Human autoimmune disease

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

Lupus headache is a proposed, specific headache disorder in patients with systemic lupus erythematosus (SLE). Research shows that headache is a symptom commonly described by SLE patients —57% in one meta-analysis, ranging in different studies from 33% to 78%; of which migraine 31.7% and tension-type headache 23.5%. The existence of a special lupus headache is contested, although few high-quality studies are available to form definitive conclusions.

Diffuse proliferative glomerulonephritis (DPGN) is a type of glomerulonephritis that is the most serious form of renal lesions in SLE and is also the most common, occurring in 35% to 60% of patients. In absence of SLE, DPGN pathology looks more like Membranoproliferative glomerulonephritis

<span class="mw-page-title-main">Retinal vasculitis</span> Medical condition

Retinal vasculitis is inflammation of the vascular branches of the retinal artery, caused either by primary ocular disease processes, or as a specific presentation of any systemic form of vasculitis such as Behçet's disease, sarcoidosis, multiple sclerosis, or any form of systemic necrotizing vasculitis such as temporal arteritis, polyarteritis nodosa, and granulomatosis with polyangiitis, or due to lupus erythematosus, or rheumatoid arthritis. Eales disease, pars planitis, birdshot retinochoroidopathy, and Fuchs heterochromic iridocyclitis (FHI) can also cause retinal vasculitis. Infectious pathogens such as Mycobacterium tuberculosis, visceral larva migrans can also cause retinal vasculitis. Drug-induced vasculitis may involve retina as well, as seen in methamphetamine induced vasculitis.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

Blisibimod is a selective antagonist of B-cell activating factor, being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.

Autoimmune optic neuropathy (AON), sometimes called autoimmune optic neuritis, may be a forme fruste of systemic lupus erythematosus (SLE) associated optic neuropathy. AON is more than the presence of any optic neuritis in a patient with an autoimmune process, as it describes a relatively specific clinical syndrome. AON is characterized by chronically progressive or recurrent vision loss associated with serological evidence of autoimmunity. Specifically, this term has been suggested for cases of optic neuritis with serological evidence of vasculitis by positive ANA, despite the lack of meeting criteria for SLE. The clinical manifestations include progressive vision loss that tends to be steroid-responsive and steroid dependent.

<span class="mw-page-title-main">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations</span> Medical condition

Retinal vasculopathy with cerebral leukocencephalopathyand systemic manifestations is an inherited condition resulting from a frameshift mutation in the C-terminal region of the TREX1 gene. This disease affects small blood vessels, leading to damage of multiple organs including but not limited to the retina and the white matter of the central nervous system. Patients with RVCL develop vision loss, brain lesions, strokes, brain atrophy, and dementia. Patients with RVCL also exhibit other organ involvement, including kidney, liver, gastrointestinal tract, thyroid, and bone disease. Symptoms of RVCL commonly begin between ages 35 and 55, although sometimes disease onset occurs earlier or later. The overall prognosis is poor, and death can sometimes occur within 5 or 10 years of the first symptoms appearing, although some patients live more than 20 years after initial symptoms. Clinical trials are underway, as are efforts to develop personalized medicines for patients with RVCL.

Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body. It is estimated that over half of people with SLE have neuropsychiatric involvement.

Vasculitic neuropathy is a peripheral neuropathic disease. In a vasculitic neuropathy there is damage to the vessels that supply blood to the nerves. It can be as part of a systemic problem or can exist as a single-organ issue only affecting the peripheral nervous system (PNS). It is diagnosed with the use of electrophysiological testing, blood tests, nerve biopsy and clinical examination. It is a serious medical condition that can cause prolonged morbidity and disability and generally requires treatment. Treatment depends on the type but it is mostly with corticosteroids or immunomodulating therapies.

References

  1. ↑ Doyle, Mittie K. (2006). "Vasculitis associated with connective tissue disorders". Current Rheumatology Reports. 8 (4). Springer Science and Business Media LLC: 312–316. doi:10.1007/s11926-006-0015-5. ISSN   1523-3774. PMID   16839511. S2CID   33335949.
  2. 1 2 3 Leone, Patrizia; Cicco, Sebastiano; Vacca, Angelo; Dammacco, Franco; Racanelli, Vito (2016). "Vasculitis in Connective Tissue Diseases". Systemic Vasculitides: Current Status and Perspectives. Cham: Springer International Publishing. pp. 345–359. doi:10.1007/978-3-319-40136-2_30. ISBN   978-3-319-40134-8.
  3. 1 2 Janssens, Peter; Arnaud, Laurent; Galicier, Lionel; Mathian, Alexis; Hie, Miguel; Sene, Damien; Haroche, Julien; Veyssier-Belot, Catherine; Huynh-Charlier, Isabelle; Grenier, Philippe A; Piette, Jean-Charles; Amoura, Zahir (May 3, 2013). "Lupus enteritis: from clinical findings to therapeutic management". Orphanet Journal of Rare Diseases. 8 (1). Springer Science and Business Media LLC. doi: 10.1186/1750-1172-8-67 . ISSN   1750-1172. PMC   3651279 . PMID   23642042.
  4. 1 2 Schwab, Edna P.; Schumacher, H. Ralph; Freundlich, Bruce; Callegari, Peter E. (1993). "Pulmonary alveolar hemorrhage in systemic lupus erythematosus". Seminars in Arthritis and Rheumatism. 23 (1). Elsevier BV: 8–15. doi:10.1016/s0049-0172(05)80022-8. ISSN   0049-0172. PMID   8235667.
  5. 1 2 Bortoluzzi, Alessandra; Silvagni, Ettore; Furini, Federica; Piga, Matteo; Govoni, Marcello (2019). "Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence". Clinical and Experimental Rheumatology. 37 (1): 146–155. ISSN   0392-856X. PMID   29846158.
  6. 1 2 Fanouriakis, Antonis; Kostopoulou, Myrto; Alunno, Alessia; Aringer, Martin; Bajema, Ingeborg; Boletis, John N; Cervera, Ricard; Doria, Andrea; Gordon, Caroline; Govoni, Marcello; Houssiau, Frédéric; Jayne, David; Kouloumas, Marios; Kuhn, Annegret; Larsen, Janni L; Lerstrøm, Kirsten; Moroni, Gabriella; Mosca, Marta; Schneider, Matthias; Smolen, Josef S; Svenungsson, Elisabet; Tesar, Vladimir; Tincani, Angela; Troldborg, Anne; van Vollenhoven, Ronald; Wenzel, Jörg; Bertsias, George; Boumpas, Dimitrios T (March 29, 2019). "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus". Annals of the Rheumatic Diseases. 78 (6). BMJ: 736–745. doi: 10.1136/annrheumdis-2019-215089 . hdl: 11392/2403578 . ISSN   0003-4967. PMID   30926722.
  7. ↑ Kallas, Romy; Goldman, Daniel; Petri, Michelle A (2020). "Cutaneous vasculitis in SLE". Lupus Science & Medicine. 7 (1). BMJ: e000411. doi: 10.1136/lupus-2020-000411 . ISSN   2053-8790. PMC   7509964 .
  8. ↑ Drenkard, C.; Villa, A.R.; Reyes, E.; Abello, M.; Alarcón-Segovia, D. (1997). "Vasculitis in systemic lupus erythematosus". Lupus. 6 (3). SAGE Publications: 235–242. doi:10.1177/096120339700600304. ISSN   0961-2033. S2CID   19985236.
  9. ↑ Ramos-Casals, Manuel; Nardi, Norma; Lagrutta, Mariana; Brito-Zerón, Pilar; Bové, Albert; Delgado, German; Cervera, Ricard; Ingelmo, Miguel; Font, Josep (2006). "Vasculitis in Systemic Lupus Erythematosus". Medicine. 85 (2). Ovid Technologies (Wolters Kluwer Health): 95–104. doi: 10.1097/01.md.0000216817.35937.70 . ISSN   0025-7974.
  10. ↑ Gorson, Kenneth C. (2007). "Vasculitic Neuropathies". The Neurologist. 13 (1). Ovid Technologies (Wolters Kluwer Health): 12–19. doi:10.1097/01.nrl.0000252942.14928.17. ISSN   1074-7931. PMID   17215723. S2CID   41901476.
  11. ↑ Florica, Brandusa; Aghdassi, Ellie; Su, Jiandong; Gladman, Dafna D.; Urowitz, Murray B.; Fortin, Paul R. (2011). "Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus". Seminars in Arthritis and Rheumatism. 41 (2). Elsevier BV: 203–211. doi:10.1016/j.semarthrit.2011.04.001. ISSN   0049-0172. PMID   21641018.
  12. 1 2 Rodrigues, M; Galego, O; Costa, C; Jesus, D; Carvalho, P; Santiago, M; Malcata, A; Inês, L (February 26, 2017). "Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre". Lupus. 26 (13). SAGE Publications: 1440–1447. doi:10.1177/0961203317694259. ISSN   0961-2033. PMID   28420057. S2CID   10494588.
  13. ↑ Kröner, Paul T.; Tolaymat, Omar A.; Bowman, Andrew W.; Abril, Andy; Lacy, Brian E. (June 12, 2019). "Gastrointestinal Manifestations of Rheumatological Diseases". American Journal of Gastroenterology. 114 (9). Ovid Technologies (Wolters Kluwer Health): 1441–1454. doi:10.14309/ajg.0000000000000260. ISSN   0002-9270. PMID   31205138. S2CID   189945962.
  14. ↑ Ju, Ji Hyeon; Min, Jun-Ki; Jung, Chan-Kwon; Oh, Soon Nam; Kwok, Seung-Ki; Kang, Kwi Young; Park, Kyung-Su; Ko, Hyuk-Jae; Yoon, Chong-Hyeon; Park, Sung-Hwan; Cho, Chul-Soo; Kim, Ho-Youn (2009). "Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE". Nature Reviews Rheumatology. 5 (5). Springer Science and Business Media LLC: 273–281. doi:10.1038/nrrheum.2009.53. ISSN   1759-4790. PMID   19412194. S2CID   12764348.
  15. ↑ Lee, C-K (June 1, 2002). "Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis)". Annals of the Rheumatic Diseases. 61 (6). BMJ: 547–550. doi:10.1136/ard.61.6.547. ISSN   0003-4967. PMC   1754133 . PMID   12006332.
  16. ↑ Xu, Danyi; Lin, Jin (2015). "Urinary tract involvement in systemic lupus erythematosus: Coexistence with lupus mesenteric vasculitis or intestinal pseudo-obstruction?". Seminars in Arthritis and Rheumatism. 44 (4). Elsevier BV: e9. doi:10.1016/j.semarthrit.2014.05.018. ISSN   0049-0172. PMID   24953799.
  17. ↑ Banfi, Giovanni; Bertani, Tullio; Boeri, Vincenzo; Faraggiana, Tullio; Mazzucco, Giovanna; Monga, Guido; Sacchi, Giuseppe (1991). "Renal Vascular Lesions as a Marker of Poor Prognosis in Patients With Lupus Nephritis". American Journal of Kidney Diseases. 18 (2). Elsevier BV: 240–248. doi:10.1016/s0272-6386(12)80885-7. ISSN   0272-6386.
  18. ↑ Descombes, Eric; Droz, Dominique; Drouet, Ludovic; Grünfeld, Jean-Pierre; Lesavre, Philippe (1997). "Renal Vascular Lesions in Lupus Nephritis". Medicine. 76 (5). Ovid Technologies (Wolters Kluwer Health): 355–368. doi: 10.1097/00005792-199709000-00003 . ISSN   0025-7974. PMID   9352738.
  19. ↑ Wu, Li-Hua; Yu, Feng; Tan, Ying; Qu, Zhen; Chen, Meng-Hua; Wang, Su-Xia; Liu, Gang; Zhao, Ming-Hui (2013). "Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions". Kidney International. 83 (4). Elsevier BV: 715–723. doi: 10.1038/ki.2012.409 . ISSN   0085-2538.
  20. ↑ Ding, Ying; Tan, Ying; Qu, Zhen; Yu, Feng (December 20, 2019). "Renal microvascular lesions in lupus nephritis". Renal Failure. 42 (1). Informa UK Limited: 19–29. doi: 10.1080/0886022x.2019.1702057 . ISSN   0886-022X. PMC   6968586 . PMID   31858861.
  21. 1 2 Androudi, Sofia; Dastiridou, Anna; Symeonidis, Chrysanthos; Kump, Leila; Praidou, Anna; Brazitikos, Periklis; Kurup, Shree K. (September 6, 2012). "Retinal vasculitis in rheumatic diseases: an unseen burden". Clinical Rheumatology. 32 (1). Springer Science and Business Media LLC: 7–13. doi:10.1007/s10067-012-2078-1. ISSN   0770-3198. S2CID   2836199.
  22. ↑ Chin, Daniel; Gan, Nicola Y.; Holder, Graham E.; Tien, Melissa; Agrawal, Rupesh; Manghani, Mona (March 15, 2021). "Severe retinal vasculitis in systemic lupus erythematosus leading to vision threatening paracentral acute middle maculopathy". Modern Rheumatology Case Reports. 5 (2). Oxford University Press (OUP): 265–271. doi:10.1080/24725625.2021.1893961. ISSN   2472-5625. S2CID   232048767.
  23. ↑ BUTENDIECK, RONALD R.; PARIKH, KIMBERLY; STEWART, MICHAEL; DAVIDGE-PITTS, CAROLINE; ABRIL, ANDY (2012). "Systemic Lupus Erythematosus-associated Retinal Vasculitis". The Journal of Rheumatology. 39 (5): 1095–1096. doi: 10.3899/jrheum.111462 . ISSN   0315-162X. PMID   22550008.
  24. ↑ Caracciolo, Eugene A.; Marcu, Constantin B.; Ghantous, Andre; Donohue, Thomas J.; Hutchinson, Gordon (2004). "Coronary Vasculitis With Acute Myocardial Infarction in a Young Woman With Systemic Lupus Erythematosus". JCR: Journal of Clinical Rheumatology. 10 (2). Ovid Technologies (Wolters Kluwer Health): 66–68. doi:10.1097/01.rhu.0000111317.80408.16. ISSN   1076-1608. PMID   17043468.
  25. ↑ Barile-Fabris, L.; Hernández-Cabrera, M. F.; Barragan-Garfias, J. A. (July 15, 2014). "Vasculitis in Systemic Lupus Erythematosus". Current Rheumatology Reports. 16 (9). Springer Science and Business Media LLC. doi:10.1007/s11926-014-0440-9. ISSN   1523-3774. PMID   25023725. S2CID   38020123.
  26. 1 2 3 Fessler, Barri; Hoffman, Gary S (October 29, 2010). Systemic Lupus Erythematosus (5 ed.). MA, USA: Academic Press. pp. 833–845. ISBN   9780080961712 . Retrieved 18 December 2023.
  27. ↑ Nasser, Mouhamad; Cottin, Vincent (2018). "Alveolar Hemorrhage in Vasculitis (Primary and Secondary)". Seminars in Respiratory and Critical Care Medicine. 39 (4). Georg Thieme Verlag KG: 482–493. doi:10.1055/s-0038-1668533. ISSN   1069-3424. PMID   30404115. S2CID   53211301.
  28. ↑ Kallenberg, C GM; Heeringa, P (1998). "Pathogenesis of vasculitis". Lupus. 7 (4). SAGE Publications: 280–284. doi:10.1191/096120398678920109. ISSN   0961-2033.
  29. ↑ Pyrpasopoulou, Athina; Chatzimichailidou, Sofia; Aslanidis, Spyros (2012). "Vascular Disease in Systemic Lupus Erythematosus". Autoimmune Diseases. 2012. Hindawi Limited: 1–4. doi: 10.1155/2012/876456 . ISSN   2090-0422.
  30. 1 2 3 4 5 6 7 8 9 Leone, Patrizia; Prete, Marcella; Malerba, Eleonora; Bray, Antonella; Susca, Nicola; Ingravallo, Giuseppe; Racanelli, Vito (November 5, 2021). "Lupus Vasculitis: An Overview". Biomedicines. 9 (11). MDPI AG: 1626. doi: 10.3390/biomedicines9111626 . ISSN   2227-9059. PMC   8615745 . PMID   34829857.
  31. 1 2 3 4 Calle-Botero, Estefania; Abril, Andy (2020-08-26). "Lupus Vasculitis". Current Rheumatology Reports. 22 (10): 71. doi:10.1007/s11926-020-00937-0. ISSN   1534-6307. PMID   32845454. S2CID   221329029.
  32. ↑ Pyrpasopoulou, Athina; Chatzimichailidou, Sofia; Aslanidis, Spyros (2012). "Vascular disease in systemic lupus erythematosus". Autoimmune Diseases. 2012: 876456. doi: 10.1155/2012/876456 . ISSN   2090-0430. PMC   3432322 . PMID   22957213.
  33. ↑ Toledano, Pilar; Orueta, Ramón; Rodríguez-Pintó, Ignasi; Valls-Solé, Josep; Cervera, Ricard; Espinosa, Gerard (2017). "Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre". Autoimmunity Reviews. 16 (7). Elsevier BV: 750–755. doi:10.1016/j.autrev.2017.05.011. ISSN   1568-9972. PMID   28483540.
  34. ↑ Koo, B S; Hong, S; Kim, Y J; Kim, Y-G; Lee, C-K; Yoo, B (November 12, 2014). "Lupus enteritis: clinical characteristics and predictive factors for recurrence". Lupus. 24 (6). SAGE Publications: 628–632. doi:10.1177/0961203314558858. ISSN   0961-2033. PMID   25391541. S2CID   206602247.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.